

07th November 2023

The General Manager,
Department of Corporate Services
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 543308
ISIN: INE967H01017

The Manager,
Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/1, 'G' Block,
Bandra - Kurla Complex,
Mumbai - 400 051.
Symbol - KIMS
ISIN: INE967H01017

Dear Sir,

Sub: Press Release on the un-audited (Standalone & Consolidated) financial results of the Company for the quarter and half-year ended 30th September 2023.

With reference to the above-stated subject, please find enclosed herewith the Press Release on the un-audited (Standalone & Consolidated) financial results of the Company for the quarter and half-year ended 30th September 2023.

The same will also be available on the website of the Company at <https://www.kimshospitals.com/investors/Disclosures> under Regulation 46 of SEBI (LODR) Regulations, 2015/Financial Information/Press Release.

We request you to take this on record.

Thanking you,

Yours truly,

For Krishna Institute of Medical Sciences Limited

MANTHA Digitally signed
by MANTHA
UMASHA UMASHANKAR
NKAR Date: 2023.11.07
17:10:09 +05'30'

Umashankar Mantha

Company Secretary & Compliance Officer

Enclosed: As above

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558



Press Release

7th November 2023, Hyderabad, India

- **Consolidated Revenue of INR 655 Cr, an increase of 14.3% YoY and 7.6% QoQ basis.**
- **Operating EBITDA of INR 180 Cr, an increase of 11.5% YoY and 12.5% QoQ basis.**

The Board of Directors of Krishna Institute of Medical Sciences Limited (KIMS Hospitals) today approved the financial results for the period ending 30th September 2023. A snapshot of Consolidated Financial and Operational highlights as follows:

- Gross revenue at INR 655 Cr, a growth of 14.3% on a YoY and 7.6% on a QoQ basis.
- Reported Operating EBITDA of INR 180 Cr, an increase of 11.5% YoY and 12.5% QoQ basis.
- Reported EBITDA margin at 27.5% vs. 28.3% in Q2 FY23 and 26.3% in Q1 FY24.
- PAT at INR 101 Cr in Q2 FY24 against INR 91 Cr (*before one-offs*) and INR 87 Cr in Q2 FY23 and Q1 FY24 respectively.
- Conducted 4.13 lakhs OPD consults in Q2 FY24, up by 10% on YoY and 8% on QoQ basis.
- Bed occupancy in Q2 FY24 at 76.4%, up by 3.8% on YOY and 6% QoQ basis.
- ARPOB at INR 31,140 in Q2 FY24, 6.5% growth YOY and marginal decline of 1.8% on QoQ basis.
- Cash and Cash Equivalents at INR 104 Cr in Q2 FY24. Net Debt to Equity ratio at 0.26

Financial Highlights - Consolidated:

- Consolidated Revenue grew by 14.3% on a YoY and 7.6% on a QoQ basis to INR 655 Cr
- Consolidated EBITDA (Pre-INDAS and excluding Other Income) grew by 19.1% on a YoY and 11.3% on a QoQ basis to INR 172 Cr
- Consolidated EBITDA (Pre-INDAS and excluding Other Income) Margin stands at 26.4%, showing an increase of 0.9% from previous quarter.
- Consolidated PAT increased by 11.0% (*before one offs*) on a YoY and by 16.9% on a QoQ basis to INR 101 Cr. Consolidated EPS declined by 5.3% on a YoY and increased by 13.9% on a QoQ basis to INR 11.5

Amt in Cr

Particulars	Consolidated - FY24 Q2 Results				
	Q2 FY 24	Q1 FY 24	Q2 FY 23	QoQ	YoY
Total Income	655.4	609.1	573.3		
Less : Other Income	2.9	3.1	9.2		
Revenue from Operations	652.5	606.0	564.1	7.7%	15.7%
PBT*	138.6	118.6	122.6	16.9%	13.0%
Add : Interest	8.9	9.3	7.9		
Add : Depreciation	32.6	32.3	31.1		
Reported EBITDA (Including other income) as per Financials	180.2	160.2	161.6	12.5%	11.5%
Less : Other Income	2.9	3.1	9.2		
Less : INDAS	5.0	2.3	7.7		
EBITDA Pre INDAS & Other Income	172.3	154.8	144.7	11.3%	19.1%
EBITDA % to Revenue from Operations	26.4%	25.5%	25.7%		

*PBT are excluding one-time items of - fair value gain on acquisition of control of Rs 148.3 Mn in FY23 Q2 & Share of loss of associate of Rs.0.22mn in Q2 FY24

Operational Highlights- Consolidated

- Sunshine and Nagpur units integrating well as per KIMS practices.
- IVF Started at Nagpur Unit
- There was consistent growth on IP volumes and OP volumes on QoQ as well as YoY basis. Details in the table below.

Group

Particulars	FY24 Q2 Results				
	Q2 FY 24	Q1 FY 24	Q2 FY 23	QoQ	YoY
IP Volumes	51,115	46,205	46,616	10.6%	9.7%
OP Volumes	4,13,020	3,82,387	3,75,188	8.0%	10.1%
ARPOB (Rs)	31,140	31,697	29,237	-1.8%	6.5%
ARPP(Rs)	1,27,959	1,31,363	1,21,302	-2.6%	5.5%

Clinical achievements during the Quarter:

- A 14-month baby's kidney was transplanted successfully on a 58-year-old woman at KIMS Hospitals, Secunderabad
- In a first-of-its-kind operation in Hyderabad, a 65-year-old woman gets a stent in her spine, at KIMS Hospitals, Kondapur
- A rare reproductive medical condition, only 300 cases reported worldwide, was treated successfully at KIMS Hospitals, Secunderabad
- A 10-day-old baby suffering from multi-organ failure was successfully discharged at KIMS Saveera Hospital, Anantapur
- First ever case of Carotid artery stenting performed in southern Andhra Pradesh at KIMS Saveera Hospital, Anantapur
- In the rarest of the rare cases reported, a 5-year-old with Absence Seizures case was successfully treated at KIMS Hospitals, Kurnool
- In a first of its kind case, Kidneys were extracted laparoscopically for Kidney transplantation at KIMS Hospitals, Kurnool.

Announcing Q2 FY24 results, **Dr. B Bhaskar Rao, CMD, KIMS Hospitals**, said:

“The second quarter has been a busy one for us. We have seen patient footfalls steadily increasing at all our centers. I am particularly pleased to see that our clinical additions in the newly acquired units (Sunshine & Nagpur) has resulted in an uptick in performances across all fronts. Our expansion plans at Bangalore, Nashik and Mumbai are progressing as per schedule. I am optimistic that we are on track to achieve our targets for FY 24.”

State-of-the-art Medical Infrastructure for Cancer treatment:

KIMS Hospitals has placed an order for procuring radiation therapy systems for its Group of hospital units, worth approximately USD 38-40 Million from Elekta, a leader in precision radiation therapy which is headquartered in Stockholm, Sweden. Elektra equipment will be deployed in a phased manner over a period of 3 years in different locations across our group. With the deployment of the Elekta radiation therapy in the KIMS Group of hospitals, cancer patients would benefit from the suite of advanced precision radiation therapy solutions.

About KIMS Hospitals:

Founded by Dr. B. Bhaskara Rao and headquartered in Hyderabad, KIMS Hospitals is one of the largest corporate healthcare groups in Telangana and AP, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The Krishna Institute of Medical Sciences (KIMS) has a network of 12 hospitals and 3,975 beds spread across Telangana (Secunderabad, Kondapur, Gachibowli and Paradise Circle), Andhra Pradesh (Nellore, Rajahmundry, Srikakulam, Ongole, Vizag, Anantapur and Kurnool) and Maharashtra (Nagpur). The group offers a comprehensive bouquet of healthcare services across 40 specialties and super-specialties. The flagship hospital of the group at Secunderabad is one of the largest hospitals in India with a capacity of 1000 beds at a single location in the heart of the city.

For further details, please contact us at sachin@kimshospitals.com